The clinical efficacy and safety assessment of lenvatinib and PD-1 inhibitors combined with TACE-HAIC in the treatment of primary liver cancer

Abstract

Abstract: Objective To analyze the clinical efficacy and safety of lenvatinib (abbreviated as Len in the group) and PD-1 inhibitor combined with transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy (TACE-HAIC) in the treatment of primary liver cancer (PLC). Methods A total of 84 patients with middle and advanced primary liver cancer treated from December 2022 to September 2024 at Pangang Group General Hospital were selected. Among them, 49 patients (58.33%) treated with Len+PD-1+TACE-HAIC were included in the observation group, and 35 patients (41.67%) treated with Len+TACE were included in the control group. Clinical data of the two groups were collected and analyzed to compare adverse reactions, efficacy, and survival after different treatment methods. Results There were no significant differences in general information such as gender, age, BMI, Child-Pugh score, history of TACE, history of hepatitis, metastasis, and family history between the observation group and the control group (P>0.05). However, there was a significant difference in the maximum diameter of the tumor, with the observation group having a significantly larger maximum tumor diameter than the control group [(6.12±1.42)cm vs. (5.22±1.20)cm, P=0.003]. According to the follow-up data, the overall survival (OS) of the observation group was significantly higher than that of the control group (P<0.001), and the progression-free survival (PFS) of the observation group was significantly longer than that of the control group (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, with a statistically significant difference (P<0.05). Compared with the control group, the overall response rate and disease control rate after treatment in the observation group were higher than that of the control group: 38.78% vs. 25.71% and 95.92% vs. 71.43%, respectively. Conclusion The combination of lenvatinib, PD-1 inhibitors, and TACE-HAIC can effectively control the progression of primary liver cancer, extend the survival time of patients, and has a good safety profile.

Key words: Primary liver cancer, TACE, HAIC, Clinical efficacy

Zhang Heng, Zou Ling, Li Jie, Liu Zhaohong, Zhang Zaihua, Yin Dengju. The clinical efficacy and safety assessment of lenvatinib and PD-1 inhibitors combined with TACE-HAIC in the treatment of primary liver cancer[J]. Chinese Hepatolgy, 2026, 31(7): 989-993.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] 王闯胜, 朱培欣, 石佳. 单纯仑伐替尼靶向治疗原发性与转移性肝癌患者的效果对比研究[J]. 中国合理用药探索, 2023, 20(5): 86-91.
[3] 陈亦晨, 曲晓滨, 孙良红, 等. 2002—2019年上海市浦东新区居民肝癌死亡特征及减寿率分析[J]. 中国全科医学, 2021, 24(12): 1517-1522.
[4] Anwanwan D, Singh S K, Singh S, et al. Challenges in liver cancer and possible treatment approaches[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(1):188314.
[5] Xing R, Gao J, Cui Q, et al. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma[J]. Front Immunol, 2021, 12: 783236.
[6] Ji S, Feng L, Fu Z, et al. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology[J]. Sci Transl Med, 2023, 15(706): 26.
[7] Kudo M, Finn R S, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[8] Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma[J]. Hepatology, 2023, 77(5): 1773-1796.
[9] Buttell A,Qiu W. The action and resistance mechanisms of lenvatinib in liver cancer[J]. Mol Carcinog, 2023, 62(12): 1918-1934.
[10] Yi C, Chen L, Lin Z, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC[J]. Hepatology, 2021, 74(5): 2544-2560.
[11] Zhou C, Sun B Y, Zhou P Y, et al. MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway[J]. Clin Immunol, 2023, 256(109770): 17.
[12] Li Z C, Wang J, Liu H B, et al. Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy[J]. Cell Rep, 2024, 43(3): 27.
[13] Yang X, Chen B, Wang Y, et al. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients[J]. Hepatol Int, 2023, 17(3): 709-719.
[14] Zhang W, Tong S, Hu B, et al. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial[J]. J Immunother Cancer, 2023, 11(9): e007366.
[15] Demirtas C O, Ricco G, Ozdogan O C, et al. Practicality and potential restrictions of unresectable hepatocellular carcinoma prognostic index[J].Hepatol Commun, 2022, 6(12): 3600-3601.
[16] Aramaki O, Takayama T, Moriguchi M, et al. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): a multicentre, randomised controlled phase 2/3 trial[J]. Eur J Cancer, 2021, 157: 373-382.
[17] Sidaway P. HAIC-FO improves outcomes in HCC[J]. Nat Rev Clin Oncol, 2022, 19(3):150.
[18] Yuan Y, He W, Yang Z, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study[J]. Int J Surg, 2023, 109(5): 1222-1230.
[19] Liu J, Zhang J, Wang Y, et al. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis[J].Medicine (Baltimore). 2022, 101(51):e32390.